162 related articles for article (PubMed ID: 23319864)
1. A phase I pharmacokinetic study of ursolic acid nanoliposomes in healthy volunteers and patients with advanced solid tumors.
Zhu Z; Qian Z; Yan Z; Zhao C; Wang H; Ying G
Int J Nanomedicine; 2013; 8():129-36. PubMed ID: 23319864
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of panaxatrol disuccinate sodium, a novel anti-cancer drug from Panax notoginseng, in healthy volunteers and patients with advanced solid tumors.
Yan Z; Zhu ZL; Wang HQ; Li W; Mi YX; Liu CX
Acta Pharmacol Sin; 2010 Nov; 31(11):1515-22. PubMed ID: 21052087
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of toxicity and single-dose pharmacokinetics of intravenous ursolic acid liposomes in healthy adult volunteers and patients with advanced solid tumors.
Wang XH; Zhou SY; Qian ZZ; Zhang HL; Qiu LH; Song Z; Zhao J; Wang P; Hao XS; Wang HQ
Expert Opin Drug Metab Toxicol; 2013 Feb; 9(2):117-25. PubMed ID: 23134084
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
Zhao RK; Cheng G; Tang J; Song J; Peng WX
Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic characteristics of vincristine sulfate liposomes in patients with advanced solid tumors.
Yan Z; Zhu ZL; Qian ZZ; Hu G; Wang HQ; Liu WH; Cheng G
Acta Pharmacol Sin; 2012 Jun; 33(6):852-8. PubMed ID: 22669119
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry.
Liu MY; Meng SN; Wu HZ; Wang S; Wei MJ
Clin Ther; 2008 Apr; 30(4):641-53. PubMed ID: 18498913
[TBL] [Abstract][Full Text] [Related]
8. Quantitation of ursolic acid in human plasma by ultra performance liquid chromatography tandem mass spectrometry and its pharmacokinetic study.
Xia Y; Wei G; Si D; Liu C
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jan; 879(2):219-24. PubMed ID: 21169069
[TBL] [Abstract][Full Text] [Related]
9. A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors.
Yan Z; Zhu Z; Li K; Chen P; Wang L; Huang C; Xue J; Liu M
Cancer Chemother Pharmacol; 2011 Apr; 67(4):955-61. PubMed ID: 21191594
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study.
Jiang J; Tian L; Huang Y; Li Y; Xu L
Clin Ther; 2008 Jul; 30(7):1290-9. PubMed ID: 18691988
[TBL] [Abstract][Full Text] [Related]
11. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial to evaluate the multiple-dose safety and antitumor activity of ursolic acid liposomes in subjects with advanced solid tumors.
Qian Z; Wang X; Song Z; Zhang H; Zhou S; Zhao J; Wang H
Biomed Res Int; 2015; 2015():809714. PubMed ID: 25866811
[TBL] [Abstract][Full Text] [Related]
13. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
Abbas R; Hug BA; Leister C; Gaaloul ME; Chalon S; Sonnichsen D
Cancer Chemother Pharmacol; 2012 Jan; 69(1):221-7. PubMed ID: 21691746
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors.
Fan B; Mellinghoff IK; Wen PY; Lowery MA; Goyal L; Tap WD; Pandya SS; Manyak E; Jiang L; Liu G; Nimkar T; Gliser C; Prahl Judge M; Agresta S; Yang H; Dai D
Invest New Drugs; 2020 Apr; 38(2):433-444. PubMed ID: 31028664
[TBL] [Abstract][Full Text] [Related]
15. A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.
Ramaswamy B; Phelps MA; Baiocchi R; Bekaii-Saab T; Ni W; Lai JP; Wolfson A; Lustberg ME; Wei L; Wilkins D; Campbell A; Arbogast D; Doyle A; Byrd JC; Grever MR; Shah MH
Invest New Drugs; 2012 Apr; 30(2):629-38. PubMed ID: 20938713
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
[TBL] [Abstract][Full Text] [Related]
18. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
19. Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.
Martin DE; Blum R; Doto J; Galbraith H; Ballow C
Clin Pharmacokinet; 2007; 46(7):589-98. PubMed ID: 17596104
[TBL] [Abstract][Full Text] [Related]
20. Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects.
Graham RA; Hop CE; Borin MT; Lum BL; Colburn D; Chang I; Shin YG; Malhi V; Low JA; Dresser MJ
Br J Clin Pharmacol; 2012 Nov; 74(5):788-96. PubMed ID: 22458643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
